Have any questions? 706-721-6582 or cts@augusta.edu
- (EB05) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Eb05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients with Covid-19
Clinical Trial
(EB05) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Eb05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients with Covid-19
This study is for adults ages 18 and older who have COVID-19 infection and are in the hospital. The purpose is to see if a new drug, EB05, is safe and more effective than standard treatment only.
Eligibility Criteria
- To be eligible, subjects must * be 18 of age or older * have a confirmed diagnosis of SARS-CoV-2 * be hospitalized * be free of other serious or underlying health conditions or recent history of health events
RESEARCH. INNOVATION. DISCOVERY.